Search results
Showing 241 to 255 of 393 results for heart failure
Evidence-based recommendations on golimumab (Simponi) for treating rheumatoid arthritis in adults.
Early and locally advanced breast cancer: diagnosis and management (NG101)
This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person's individual preferences.
NICE has developed a medtech innovation briefing (MIB) on CytoSorb therapy for sepsis .
ENDURALIFE powered CRT-D devices for treating heart failure (MTG33)
We have moved Medical technologies guidance 33 to become HealthTech guidance 433. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Evidence-based recommendations on cetuximab (Erbitux), bevacizumab (Avastin) and panitumumab (Vectibix) for treating metastatic colorectal cancer in adults.
Read biographies for all members of NICE's indicator advisory committee.
Evidence-based recommendations on multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis.
NICE has developed a medtech innovation briefing (MIB) on DuraGraft for preserving vascular grafts .
Temperature control to improve neurological outcomes after cardiac arrest (IPG782)
Evidence-based recommendations on temperature control to improve neurological outcomes after cardiac arrest. This involves controlling a person’s body temperature while they are still unconscious after their heart has been restarted. Either their body is kept at a normal temperature of between 36.5°C and 37.5°C to prevent fever, or it is cooled to between 32.0°C and 36.0°C (therapeutic hypothermia).
View recommendations for IPG782Show all sections
Extracorporeal membrane oxygenation (ECMO) for acute heart failure in adults (IPG482)
This guidance has been updated and replaced by NICE interventional procedures guidance 807, 808 and 810.
TactiCath Quartz catheter for percutaneous radiofrequency ablation in atrial fibrillation (MIB60)
NICE has developed a medtech innovation briefing (MIB) on the TactiCath Quartz catheter for percutaneous radiofrequency ablation in atrial fibrillation
Specialist neonatal respiratory care for babies born preterm (QS193)
This quality standard covers neonatal respiratory support in hospital for babies born preterm (before 37 weeks of pregnancy). It describes high-quality care in priority areas for improvement.
View quality statements for QS193Show all sections
Sections for QS193
- Quality statements
- Quality statement 1: Respiratory support soon after birth
- Quality statement 2: Minimally invasive administration of surfactant
- Quality statement 3: Invasive ventilation
- Quality statement 4: Oxygen saturation
- Quality statement 5: Involving parents and carers
- Update information
- About this quality standard
Etelcalcetide for treating secondary hyperparathyroidism (TA448)
Evidence-based recommendations on etelcalcetide (Parsabiv) for treating secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis.
Evidence-based recommendations on pixantrone (Pixuvri) for treating relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma in adults.
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)
Evidence-based recommendations on pertuzumab (Perjeta) for treating HER2-positive, locally recurrent or metastatic (secondary) breast cancer that has not been treated with chemotherapy or targeted HER-2 therapy before, in adults.